As of 2025-09-18, the Relative Valuation of GT Biopharma Inc (GTBP) is (45.41) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.79 USD, the upside of GT Biopharma Inc based on Relative Valuation is -5853.8%.
The range of the Relative Valuation is (40.33) - (56.59) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.3x - 17.3x | 13.9x |
| Forward P/E multiples | 12.2x - 20.2x | 13.8x |
| Fair Price | (40.33) - (56.59) | (45.41) |
| Upside | -5209.9% - -7270.5% | -5853.8% |
| Date | P/E |
| 2025-09-12 | -0.25 |
| 2025-09-11 | -0.23 |
| 2025-09-10 | -0.24 |
| 2025-09-09 | -0.23 |
| 2025-09-08 | -0.26 |
| 2025-09-05 | -0.29 |
| 2025-09-04 | -0.28 |
| 2025-09-03 | -0.29 |
| 2025-09-02 | -0.27 |
| 2025-08-29 | -0.29 |
| 2025-08-28 | -0.30 |
| 2025-08-27 | -0.35 |
| 2025-08-26 | -0.35 |
| 2025-08-25 | -0.33 |
| 2025-08-22 | -0.34 |
| 2025-08-21 | -0.33 |
| 2025-08-20 | -0.33 |
| 2025-08-19 | -0.41 |
| 2025-08-18 | -0.45 |
| 2025-08-15 | -0.41 |
| 2025-08-14 | -0.44 |
| 2025-08-13 | -0.51 |
| 2025-08-12 | -0.53 |
| 2025-08-11 | -0.53 |
| 2025-08-08 | -0.55 |
| 2025-08-07 | -0.56 |
| 2025-08-06 | -0.53 |
| 2025-08-05 | -0.54 |
| 2025-08-04 | -0.54 |
| 2025-08-01 | -0.55 |
| 2025-07-31 | -0.57 |
| 2025-07-30 | -0.61 |
| 2025-07-29 | -0.62 |
| 2025-07-28 | -0.64 |
| 2025-07-25 | -0.63 |
| 2025-07-24 | -0.65 |
| 2025-07-23 | -0.65 |
| 2025-07-22 | -0.61 |
| 2025-07-21 | -0.62 |
| 2025-07-18 | -0.63 |
| 2025-07-17 | -0.62 |
| 2025-07-16 | -0.62 |
| 2025-07-15 | -0.61 |
| 2025-07-14 | -0.65 |
| 2025-07-11 | -0.68 |
| 2025-07-10 | -0.70 |
| 2025-07-09 | -0.65 |
| 2025-07-08 | -0.63 |
| 2025-07-07 | -0.66 |
| 2025-07-03 | -0.85 |